Can a low-dose drug wake up the immune system against breast cancer?
NCT ID NCT04891068
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a low dose of the drug azacitidine, given before surgery, can increase immune cells (called tumor-infiltrating lymphocytes) in the tumors of people with high-risk early-stage breast cancer. About 40 participants will receive the drug for a short time before their planned surgery. The goal is to see if the drug makes the tumor more visible to the immune system, which could lead to better treatment options in the future.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER INVASIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Illinois Cancer Center
RECRUITINGChicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartwatch could spot nerve damage before it starts
- Tailored radiation may spare breast cancer patients from arm swelling
- Six-Gene clue: could a simple test forecast lung spread in breast cancer?
- Can a short, High-Dose radiation blast before surgery improve breast cancer care?
- Can a smart light beam help surgeons remove every last cancer cell?
- Skipping the armpit: a trial tests whether partial breast radiation alone is enough